Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells
- PMID: 19777619
- PMCID: PMC2752005
- DOI: 10.3748/wjg.15.4582
Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells
Abstract
Aim: To evaluate the effects of four types of preoperative transcatheter arterial chemoembolization (TACE) on angiogenesis of hepatocellular carcinoma (HCC) cells.
Methods: A total of 136 patients with HCC underwent liver resection. One to five courses of TACE prior to liver resection were performed in 79 patients (TACE group), in which one to four courses of chemotherapy alone were performed in 11 patients (group A); one to five courses of chemotherapy combined with iodized oil were performed in 33 patients (group B); one to three courses of chemotherapy combined with iodized oil and gelatin sponge were performed in 23 patients (group C); one to three courses of chemotherapy combined with iodized oil, ethanol and gelatin sponge were performed in 12 patients (group D). The other 57 patients only received liver resection (non-TACE group). The microvessels were marked by CD31. The expression of CD31 and vascular endothelial growth factor (VEGF) protein were detected by immunohistochemical methods.
Results: The mean microvessel density (MVD) in HCC cells was significantly higher in groups A, B, C and D than in the non-TACE group (P < 0.05). The expression of VEGF protein in HCC cells were significantly higher in groups A, B, C and D than in the non-TACE group (P < 0.05). MVD and the expression of VEGF protein were positively correlated. Mean MVD and the expression of VEGF protein were closely related to the number of courses of TACE and the interval of TACE.
Conclusion: Four different types of preoperative TACE regimens enhanced angiogenesis in HCC cells by up-regulating the expression of VEGF protein. It is necessary to repress angiogenesis of liver cancer after TACE.
Figures
Similar articles
-
Effect of preoperative transcatheter arterial chemoembolization on proliferation of hepatocellular carcinoma cells.World J Gastroenterol. 2007 Sep 7;13(33):4509-13. doi: 10.3748/wjg.v13.i33.4509. World J Gastroenterol. 2007. PMID: 17724810 Free PMC article.
-
Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells.Chin Med J (Engl). 2003 Feb;116(2):203-7. Chin Med J (Engl). 2003. PMID: 12775230
-
Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization.Hepatogastroenterology. 2012 Jul-Aug;59(117):1566-8. doi: 10.5754/hge12138. Hepatogastroenterology. 2012. PMID: 22456329 Clinical Trial.
-
The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.Korean J Radiol. 2009 Sep-Oct;10(5):425-34. doi: 10.3348/kjr.2009.10.5.425. Epub 2009 Aug 25. Korean J Radiol. 2009. PMID: 19721826 Free PMC article. Review.
-
Polymeric materials for embolic and chemoembolic applications.J Control Release. 2016 Oct 28;240:414-433. doi: 10.1016/j.jconrel.2016.02.033. Epub 2016 Feb 26. J Control Release. 2016. PMID: 26924353 Free PMC article. Review.
Cited by
-
A cellular senescence-related signature for predicting prognosis, immunotherapy response, and candidate drugs in patients treated with transarterial chemoembolization (TACE).Discov Oncol. 2024 Jul 8;15(1):271. doi: 10.1007/s12672-024-01116-8. Discov Oncol. 2024. PMID: 38976093 Free PMC article.
-
Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion.World J Gastrointest Surg. 2023 Jan 27;15(1):19-31. doi: 10.4240/wjgs.v15.i1.19. World J Gastrointest Surg. 2023. PMID: 36741072 Free PMC article. Review.
-
Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2021 May 17;8:421-434. doi: 10.2147/JHC.S304275. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 34041204 Free PMC article. Clinical Trial.
-
Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma.Cancers (Basel). 2023 May 12;15(10):2738. doi: 10.3390/cancers15102738. Cancers (Basel). 2023. PMID: 37345074 Free PMC article. Review.
-
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.Cancer. 2013 Mar 1;119(5):1042-9. doi: 10.1002/cncr.27859. Epub 2012 Nov 6. Cancer. 2013. PMID: 23132335 Free PMC article. Clinical Trial.
References
-
- McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:3–23. - PubMed
-
- Ramsey WH, Wu GY. Hepatocellular carcinoma: update on diagnosis and treatment. Dig Dis. 1995;13:81–91. - PubMed
-
- Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang BH, Lin ZY, Lu JZ, Liu KD, Fan Z, Zeng ZC. Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection. World J Surg. 1995;19:47–52. - PubMed
-
- Cai J, Hu J, Che X, Zhao J, Bi X, Shao Y. Prognosis of primary liver carcinoma treated with local resection. Chin Med J (Engl) 2003;116:187–190. - PubMed
-
- Ezaki T, Koyanagi N, Yamagata M, Kajiyama K, Maeda T, Sugimachi K. Postoperative recurrence of solitary small hepatocellular carcinoma. J Surg Oncol. 1996;62:115–122. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous